Progression-free survival
Updated median investigator-assessed PFS was 16.5 months (95% CI 12.7, 20.2) in the pertuzumab arm and 12.5 months (95% CI 10.4, 14.6) in the placebo arm (Fig. Investigator-assessed PFS in 